Variability in Contemporary Heparin Prescription and Activated Clotting Time Monitoring During Percutaneous Coronary Intervention: Call for Up-To-Date Evidence-Based Guidelines

Unfractionated heparin (UFH) is the preferred anticoagulant agent in percutaneous coronary intervention (PCI) procedures for minimising the risk of thrombotic complications. Because of the narrow therapeutic range of UFH, some society guidelines have advocated the use of the activated clotting time (ACT) test to monitor anticoagulation intensity during PCI to reduce thrombotic and bleeding complications. We aimed to assess the current practice of UFH prescription and its monitoring in Australia and New Zealand (ANZ).

Source: Heart, Lung and Circulation - November 21, 2023 Category: Cardiology Authors: Omar Al-Mukhtar, Dion Stub, Christopher M. Reid, Sidney Lo, Jeffery Lefkovits, Antony Walton, Derek P. Chew, Andy Yong, Stephen J. Nicholls, Nicholas Cox, Karlheinz Peter, William Chan Tags: Original Article Source Type: research